Compugen touts ovarian cancer data in combo with Opdivo, anti-TIGIT from ex-partner Bristol Myers
Compugen presented a batch of data from early-stage trials of its anti-PVRIG candidate in dual and triple combination studies, including one with an anti-TIGIT therapy, but the pairings are no longer part of the biotech’s strategy after it recently axed a yearslong Bristol Myers Squibb collaboration.
And, for a brief period this fall, the indication was not a focus of the biotech’s future development plans, but Tuesday’s data are enough to shore up confidence for another study in platinum resistant ovarian cancer, the Holon, Israel-based drug developer said Tuesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.